Page 57 - Read Online

Page 18 of 19 Kalloo et al. Metab Target Organ Damage 2023;3:7 https://dx.doi.org/10.20517/mtod.2022.26

45. Mai L, Wen W, Qiu M, et al. Association between prediabetes and adverse outcomes in heart failure. Diabetes Obes Metab
2021;23:2476-83. DOI
46. Kramer CK, Campbell S, Retnakaran R. Gestational diabetes and the risk of cardiovascular disease in women: a systematic review and
meta-analysis. Diabetologia 2019;62:905-14. DOI PubMed
47. Bailey CJ. Uric acid and the cardio-renal effects of SGLT2 inhibitors. Diabetes Obes Metab 2019;21:1291-8. DOI PubMed
48. Ferreira JP, Inzucchi SE, Mattheus M, et al. Empagliflozin and uric acid metabolism in diabetes: a post hoc analysis of the EMPA-
REG OUTCOME trial. Diabetes Obes Metab 2022;24:135-41. DOI PubMed PMC
49. McDowell K, Welsh P, Docherty KF, et al. Dapagliflozin reduces uric acid concentration, an independent predictor of adverse
outcomes in DAPA-HF. Eur J Heart Fail 2022;24:1066-76. DOI PubMed PMC
50. Davies MJ, Trujillo A, Vijapurkar U, Damaraju CV, Meininger G. Effect of canagliflozin on serum uric acid in patients with type 2
diabetes mellitus. Diabetes Obes Metab 2015;17:426-9. DOI PubMed PMC
51. Duell PB, Welty FK, Miller M, et al; American Heart Association Council on Arteriosclerosis; Thrombosis and Vascular Biology;
Council on Hypertension; Council on the Kidney in Cardiovascular Disease; Council on Lifestyle and Cardiometabolic Health; and
Council on Peripheral Vascular Disease. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the
American heart association. Arterioscler Thromb Vasc Biol 2022;42:e168-85. DOI
52. Androutsakos T, Nasiri-Ansari N, Bakasis AD et al. SGLT-2 Inhibitors in NAFLD: expanding their role beyond diabetes and
cardioprotection. Int J Mol Sci 2022;13:3107. DOI PubMed PMC
53. Takahashi H, Kessoku T, Kawanaka M, et al. Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD.
Hepatol Commun 2022;6:120-32. DOI PubMed PMC
54. Akuta N, Kawamura Y, Fujiyama S, et al. Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes
mellitus: a 5-year follow-up study. Hepatol Commun 2022;6:2286-97. DOI PubMed PMC
55. Takeshita Y, Honda M, Harada K, et al. Comparison of tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in
participants with type 2 diabetes: a randomized, 48-week, open-label, active-controlled trial. Diabetes Care 2022;45:2064-75. DOI
PubMed PMC
56. Available from: https://kdigo.org/wp-content/uploads/2022/03/KDIGO-2022-Diabetes-Management-GL_Public-Review-
draft_1Mar2022.pdf [Last accessed on 24 May 2023].
57. Available from: https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/early-stop-chronic-kidney-disease-trial-
efficacy [Last accessed on 24 May 2023].
58. Bakris GL, Agarwal R, Anker SD, et al; FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in
type 2 diabetes. N Engl J Med 2020;383:2219-29. DOI PubMed
59. Pitt B, Filippatos G, Agarwal R, et al; FIGARO-DKD Investigators. Cardiovascular events with finerenone in kidney disease and type
2 diabetes. N Engl J Med 2021;385:2252-63. DOI PubMed
60. Agarwal R, Filippatos G, Pitt B, et al; FIDELIO-DKD and FIGARO-DKD investigators. Cardiovascular and kidney outcomes with
finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 2022;43:474-84.
DOI PubMed PMC
61. Neuen BL, Oshima M, Agarwal R, et al. Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2
diabetes: a meta-analysis of individual participant data from randomized, controlled trials. Circulation 2022;145:1460-70. DOI
62. Available from: https://clinicaltrials.gov/ct2/show/NCT05254002 [Last accessed on 24 May 2023].
63. Marso SP, Bain SC, Consoli A, et al; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2
diabetes. N Engl J Med 2016;375:1834-44. DOI PubMed
64. Gerstein HC, Colhoun HM, Dagenais GR, et al; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes
(REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019;394:121-30. DOI PubMed
65. Gerstein HC, Colhoun HM, Dagenais GR, et al; REWIND Investigators. Dulaglutide and renal outcomes in type 2 diabetes: an
exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet 2019;394:131-8. DOI PubMed
66. Rossing P, Baeres FMM, Bakris G, et al. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly
semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant ;2023:gfad009. DOI
67. Frías JP, Auerbach P, Bajaj HS, et al. Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2
diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes Endocrinol 2021;9:563-74. DOI
68. Frias JP, Bonora E, Nevarez Ruiz L, et al. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in
metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diabetes Care 2021;44:765-73. DOI
PubMed PMC
69. Davies M, Færch L, Jeppesen OK, et al; STEP 2 Study Group. Semaglutide 2·4 mg once a week in adults with overweight or obesity,
and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 2021;397:971-84.
DOI
70. Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients
with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 2021;398:143-55. DOI
71. Frías JP, Davies MJ, Rosenstock J, et al; SURPASS-2 Investigators. Tirzepatide versus semaglutide Once weekly in patients with type
2 diabetes. N Engl J Med 2021;385:503-15. DOI
72. Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or